Wendy R. Parulekar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wendy R. Parulekar has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
- Bingshu E. Chen
Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada
23 shared publications - Karen A. Gelmon
BC Cancer—Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada
22 shared publications - Alexander Fortuna
12Genome Sequence Informatics, Ontario Institute for Cancer Research, Toronto, Canada
20 shared publications - Angela DeLuca
10Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada
20 shared publications - Anil Abraham Joy
Department of Oncology, University of Alberta, 11560 University Avenue NW, Edmonton, AB T6G 1Z2, Canada
20 shared publications - Christine Desbiens
Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, Canada
20 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Patterns of Early and Late Recurrence Across Breast Cancer Subtypes in the Canadian Cancer Trials Group MA.32 Trial
Purpose: We describe patterns of early and late recurrence across breast cancer (BC) subtypes (luminal: estrogen and/or progesterone receptor [ER and/or PgR] positive, human epidermal growth factor receptor 2 [HER2] negative); triple negative (TN); HER2+, any ER, PgR in the Canadian Cancer Trials Group MA.32 adjuvant BC trial involving 3,649 patients with high-risk BC. Methods: Post-random assignment annual rates of local and distant recurrences as well as new breast and nonbreast primaries were calculated for each BC subtype and averaged for early (years 0-5) and late (>5 years) events. Results: Patterns of events varied across subtypes and early versus late events. The early versus late annual invasive cancer rates were 3.04 versus 2.31% (late/early 0.76) in luminal, 4.60% and 1.21% (late/early 0.35) in TN and 2.93 versus 1.47% (late/early 0.50) in HER2+. Annual early versus late rates of distant recurrence were 2.33 versus 1.72% (late/early 0.74) in luminal, 3.09 versus 0.2% (late/early 0.28) in TN, and 2.25 versus 0.71% (late/early 0.32) in HER2+. Second primaries were the most frequent late event in patients with TN and HER2+ BC. Conclusion: Risk of late cancer events differed across BC subtypes; distant recurrences were most common in luminal while second primaries were most common in TN and HER2+ BC.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Open AccessPatterns of Early and Late Recurrence Across Breast Cancer Subtypes in the Canadian Cancer Trials Group MA.32 Trial
Purpose: We describe patterns of early and late recurrence across breast cancer (BC) subtypes (luminal: estrogen and/or progesterone receptor [ER and/or PgR] positive, human epidermal growth factor receptor 2 [HER2] negative); triple negative (TN); HER2+, any ER, PgR in the Canadian Cancer Trials Group MA.32 adjuvant BC trial involving 3,649 patients with high-risk BC. Methods: Post-random assignment annual rates of local and distant recurrences as well as new breast and nonbreast primaries were calculated for each BC subtype and averaged for early (years 0-5) and late (>5 years) events. Results: Patterns of events varied across subtypes and early versus late events. The early versus late annual invasive cancer rates were 3.04 versus 2.31% (late/early 0.76) in luminal, 4.60% and 1.21% (late/early 0.35) in TN and 2.93 versus 1.47% (late/early 0.50) in HER2+. Annual early versus late rates of distant recurrence were 2.33 versus 1.72% (late/early 0.74) in luminal, 3.09 versus 0.2% (late/early 0.28) in TN, and 2.25 versus 0.71% (late/early 0.32) in HER2+. Second primaries were the most frequent late event in patients with TN and HER2+ BC. Conclusion: Risk of late cancer events differed across BC subtypes; distant recurrences were most common in luminal while second primaries were most common in TN and HER2+ BC.
- Open Access
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Pretreatment diagnostic tumor somatic variants and transcriptional signatures associated with PFS. A, Frequency of variants across breast cancer driver genes in pretreatment tumor biopsies. Colors indicate variant classification (B) VAF of detected single-nucleotide variants across samples. C, HRs of PFS associated with the presence of somatic variants in driver genes. D–F, Kaplan–Meier curves of genetic variants associated with shorter PFS time in (D) TP53 and (E) CDH1. F–I, Kaplan–Meier curves of transcriptional signatures stratified by TP53 variant status associated with shorter PFS time for (F) HRD, (G) hypoxia, (H) androgen receptor, and (I) claudin low.
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Pretreatment diagnostic tumor somatic variants and transcriptional signatures associated with PFS. A, Frequency of variants across breast cancer driver genes in pretreatment tumor biopsies. Colors indicate variant classification (B) VAF of detected single-nucleotide variants across samples. C, HRs of PFS associated with the presence of somatic variants in driver genes. D–F, Kaplan–Meier curves of genetic variants associated with shorter PFS time in (D) TP53 and (E) CDH1. F–I, Kaplan–Meier curves of transcriptional signatures stratified by TP53 variant status associated with shorter PFS time for (F) HRD, (G) hypoxia, (H) androgen receptor, and (I) claudin low.
- Open Access
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Figure S9. Association between tumour-fraction, short to long fragment length ratios and progression-free survival time. A) Hazard ratio between individuals above and below each tumour fraction cut-off at baseline (green), W12 (red) and W24 (yellow). Filled in points indicate significant hazard ratios. B) Hazard ratios of tumour fraction change between baseline and W12 cfDNA associated with progression-free survival at various cut-offs. Filled in points indicate significant hazard ratios. C) Cell-free DNA fragment length distribution between individuals with shorter and longer progression free survival time of three months. D) Hazard ratio of short to long fragment length ratio on progression free survival time using various cut-offs to divide short and long. Colours indicate cfDNA sampling time at baseline (green), W12 (red) and at W24 (yellow). Filled in points are significant log-rank p-values fragment length cut-offs.
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Figure S9. Association between tumour-fraction, short to long fragment length ratios and progression-free survival time. A) Hazard ratio between individuals above and below each tumour fraction cut-off at baseline (green), W12 (red) and W24 (yellow). Filled in points indicate significant hazard ratios. B) Hazard ratios of tumour fraction change between baseline and W12 cfDNA associated with progression-free survival at various cut-offs. Filled in points indicate significant hazard ratios. C) Cell-free DNA fragment length distribution between individuals with shorter and longer progression free survival time of three months. D) Hazard ratio of short to long fragment length ratio on progression free survival time using various cut-offs to divide short and long. Colours indicate cfDNA sampling time at baseline (green), W12 (red) and at W24 (yellow). Filled in points are significant log-rank p-values fragment length cut-offs.
- Open Access
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Supplementary Table 1. Breast Cancer 360 Gene Signatures and Description
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Supplementary Table 1. Breast Cancer 360 Gene Signatures and Description
- Open Access
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Somatic variants detected in cfDNA associated with PFS time at baseline and first follow-up at week 12. A and B, Summary of genetic variants captured at (A) baseline prior to palbociclib treatment and at (B) week 12. Blue squares indicate the detection of a somatic variant in cfDNA for individuals. Barplot colors indicate variant classification. C and D, HR associated with PFS time for genetic variants detected at (C) baseline and at (D) week 12. Red points indicate gene variants significantly associated with PFS. E–I, Kaplan–Meier curves of mutations significantly associated with poor PFS time at (E–G) baseline in (E) SETD2, (F) DDR2, and (G) FGFR4 and (H and I) at week 12 in (H) TP53 and (I) ESR1. J and K, Kaplan–Meier curves of mutations associated with poor PFS in groups of genes in the (J) DNA repair pathway and (K) MAPK cascade.
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Somatic variants detected in cfDNA associated with PFS time at baseline and first follow-up at week 12. A and B, Summary of genetic variants captured at (A) baseline prior to palbociclib treatment and at (B) week 12. Blue squares indicate the detection of a somatic variant in cfDNA for individuals. Barplot colors indicate variant classification. C and D, HR associated with PFS time for genetic variants detected at (C) baseline and at (D) week 12. Red points indicate gene variants significantly associated with PFS. E–I, Kaplan–Meier curves of mutations significantly associated with poor PFS time at (E–G) baseline in (E) SETD2, (F) DDR2, and (G) FGFR4 and (H and I) at week 12 in (H) TP53 and (I) ESR1. J and K, Kaplan–Meier curves of mutations associated with poor PFS in groups of genes in the (J) DNA repair pathway and (K) MAPK cascade.
- Open Access
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Figure S7. Summary of top mutated genes in solid tissue and longitudinal liquid biopsy samples.
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Figure S7. Summary of top mutated genes in solid tissue and longitudinal liquid biopsy samples.
- Open Access
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Table 2 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Table 2 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
- Open Access
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Supplementary Figure S6. Prognostic transcriptional signatures stratified by TP53 mutation and BC360 HRD expression status in solid tissues.
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Supplementary Figure S6. Prognostic transcriptional signatures stratified by TP53 mutation and BC360 HRD expression status in solid tissues.
- Open Access
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Figure S8. Summary of biological processes associated with PFS in baseline and W12 cfDNA plasma based on mutational profiles. (A-B) Forest plots summarize HR of mutations in genes among biological processes significantly associated with PFS among (A) baseline and (B) W12 samples.
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Figure S8. Summary of biological processes associated with PFS in baseline and W12 cfDNA plasma based on mutational profiles. (A-B) Forest plots summarize HR of mutations in genes among biological processes significantly associated with PFS among (A) baseline and (B) W12 samples.
- Open Access
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Association among tumor fraction, short/long fragment length, and PFS time. A and B, Kaplan–Meier curves of cfDNA tumor fraction cutoffs most significantly associated with poor PFS time for (A) baseline samples at 2% tumor fraction and (B) week 24 samples at 6% tumor fraction. C, Change in tumor fraction between baseline and week 12 associated with PFS. D and E, Kaplan–Meier curves of fragment length ratio cutoffs (D) at baseline and (E) week 12. F, Correlation between tumor fraction and short/long fragment length ratio at baseline.
- 13 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Association among tumor fraction, short/long fragment length, and PFS time. A and B, Kaplan–Meier curves of cfDNA tumor fraction cutoffs most significantly associated with poor PFS time for (A) baseline samples at 2% tumor fraction and (B) week 24 samples at 6% tumor fraction. C, Change in tumor fraction between baseline and week 12 associated with PFS. D and E, Kaplan–Meier curves of fragment length ratio cutoffs (D) at baseline and (E) week 12. F, Correlation between tumor fraction and short/long fragment length ratio at baseline.